Affiliation:
1. Centre for Experimental Therapeutics University of Liverpool Liverpool UK
2. NIHR Liverpool Clinical Research Facility Liverpool University Hospitals NHS Foundation Trust Liverpool UK
Abstract
Phase 1 clinical drug trials critically depend on the participation of healthy volunteers to evaluate the safety and pharmacokinetics of new medicinal products. Current selection criteria and health definitions often overlook the unique health profiles of transgender and nonbinary individuals, potentially excluding them from participating in these essential early‐stage studies. This review aims to identify and discuss current knowledge gaps and considerations regarding the inclusion of transgender and nonbinary participants in phase 1 clinical drug trials. We highlight the need for research on how gender‐affirming hormone therapy may affect drug pharmacokinetics and call for the development of inclusive biological reference ranges that account for the physiological effects of hormone therapies.
Reference18 articles.
1. WillyM.Acute liver failure in women. Report to FDA's Office of Women's Health 1999.
2. Improving access for and experience of transgender and non-binary patients in clinical research: Insights from a transgender patient focus group and targeted literature reviews
3. Government Equalities Office.Trans people in the UK.Government Equalities Office 2018. Accessed February 1 2024.https://assets.publishing.service.gov.uk/media/5b3a478240f0b64603fc181b/GEO-LGBT-factsheet.pdf
4. National Institute of Health Clinical Center.Patient recruitment: healthy volunteers. Accessed February 1 2024.https://clinicalcenter.nih.gov/recruit/volunteers.html
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Moving forward to ‘put people first’;British Journal of Clinical Pharmacology;2024-06